<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9355">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05699746</url>
  </required_header>
  <id_info>
    <org_study_id>IR2022577</org_study_id>
    <nct_id>NCT05699746</nct_id>
  </id_info>
  <brief_title>CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD</brief_title>
  <official_title>A Randomized Controlled Trial of CAPEOX vs Observation in Early-stage Colorectal Cancer Patients With Positive MRD After Curative Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GeneCast Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with stage Ⅰ colorectal cancer or stage Ⅱ colon cancer usually have a good prognosis&#xD;
      and are not recommended to receive adjuvant chemotherapy after radical surgery. With the&#xD;
      advances in liquid biopsy technology, detection of circulating tumor DNA (ctDNA) can&#xD;
      effectively identify early-stage cancer patients with minimal residual disease (MRD) after&#xD;
      surgery. According to the growing number of MRD studies in solid tumor, colorectal cancer&#xD;
      patients with ctDNA-MRD detection have a poor clinical outcome and are likely to relapse&#xD;
      within two years. This study aims to assess the efficacy of adjuvant chemotherapy with&#xD;
      capecitabine plus oxaliplatin (CAPEOX) compared with conventional observation in MRD-positive&#xD;
      patients with stage I colorectal cancer and clinically low-risk stage II colon cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2023</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence-free survival</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clearance of circulating tumor DNA (ctDNA)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>CAPEOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug CAPEOX (Oxaliplatin 130 mg/m2 IV day 1, Capecitabine 1000 mg/m2, twice daily PO for 14 days, repeat every 3 weeks) for at most 8 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients undergo active surveillance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine tablets</intervention_name>
    <description>Capecitabine 1000 mg/m2, twice daily PO for 14 days, repeat every 3 weeks, for at most 8 cycles.</description>
    <arm_group_label>CAPEOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin 130 mg/m2 IV day 1, combined with Capecitabine, for at most 8 cycles.</description>
    <arm_group_label>CAPEOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Colorectal cancer confirmed by pathology, and the TNM stage (AJCC v8) is stage I or&#xD;
             stage II. Stage II patients have T3 colonic adenocarcinoma with proficient&#xD;
             mismatch-repair system (by immunohistochemistry for four mismatch repair proteins&#xD;
             MSH1, MSH2, MSH6, and PMS2) and have no the following clinical risk factors: a) less&#xD;
             than 12 lymph nodes examined; b) mucinous carcinoma; c) poor differentiation; d) bowel&#xD;
             obstruction or perforation; e) lymphatic/vascular invasion, perineural invasion; f)&#xD;
             close, indeterminate, uncertain, positive margins&#xD;
&#xD;
          2. ECOG performance status 0-1&#xD;
&#xD;
          3. No neoadjuvant therapy before surgery&#xD;
&#xD;
          4. Appropriate for active surveillance (i.e., no adjuvant chemotherapy) based on current&#xD;
             practice patterns or according to the Chinese Society of Clinical Oncology guidelines&#xD;
             for Colorectal Cancer (version 2022)&#xD;
&#xD;
          5. No history of other primary cancers in the past 3 years&#xD;
&#xD;
          6. No history of bone marrow, stem cell or organ transplant&#xD;
&#xD;
          7. Blood samples from 7 to 21 days after surgery were tested positive for ctDNA (tested&#xD;
             by MinerVa MRD assay)&#xD;
&#xD;
          8. Pregnancy test done within 14 days before randomization must be negative (for women of&#xD;
             childbearing potential only)&#xD;
&#xD;
          9. Voluntarily join the study and sign the informed consent document&#xD;
&#xD;
         10. No unstable or any medical condition that affects patient safety and study compliance&#xD;
             evaluated by researchers&#xD;
&#xD;
         11. Availability and provision of adequate surgical tumor tissue for molecular diagnostics&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with multiple primary colorectal cancers&#xD;
&#xD;
          2. Patients with another primary cancer&#xD;
&#xD;
          3. Patients have the following conditions by blood test, or have obvious contraindication&#xD;
             in adjuvant chemotherapy:&#xD;
&#xD;
               1. Moderate/severe renal impairment (GFR&lt;30 ml/min), as calculated by the Cockcroft&#xD;
                  and Gault equation&#xD;
&#xD;
               2. Absolute neutrophil count &lt;1.5×109/L&#xD;
&#xD;
               3. Platelet count &lt; 75×109/L&#xD;
&#xD;
               4. Hemoglobin &lt;90 g/L&#xD;
&#xD;
               5. Aspartate aminotransferase/Alanine aminotransferase &gt;2.5 × upper limit of normal&#xD;
&#xD;
          4. Lactating women&#xD;
&#xD;
          5. Have serious or uncontrolled medical condition that may preclude compliance with the&#xD;
             protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kefeng Ding, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kefeng Ding, MD, PhD</last_name>
    <phone>+8687784720</phone>
    <email>dingkefeng@zju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qian Xiao, MD, PhD</last_name>
    <email>qxiao3@zju.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Changhai Hospital of Shanghai</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital, Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital Zhejiang University College of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310999</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ke-Feng Ding, phD/MD</last_name>
      <phone>86-571-87784827</phone>
      <email>dingkefeng@zju.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Ke-Feng Ding, phD/MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The second hospital of Ningbo City</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <zip>315010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 16, 2023</study_first_submitted>
  <study_first_submitted_qc>January 16, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2023</study_first_posted>
  <last_update_submitted>January 16, 2023</last_update_submitted>
  <last_update_submitted_qc>January 16, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>Ding Ke-Feng</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

